We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

The National Medical Commission has launched an investigation into doctors whose foreign trips, funded by AbbVie Healthcare, ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive ...

Highlights,AbbVie lowers its FY2025 earnings estimate to $12.02 per share.,Shares of AbbVie see fluctuating performance, with ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most ...

DelveInsight's“Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.